Crohn’s & Colitis News
Below you’ll find our most recent press releases, along with other articles written by the foundation. This media content highlights the public research outcomes related to our initiatives, studies, and clinical trials. In addition, you can read our expert commentary related to research articles culled from external media sources. For a complete list of all our news content, please visit the News Archive section.
If you are a member of the media interested in speaking with a Foundation's spokesperson, contact us today.
Most Recent News
Thank you to the Allergan Foundation for investing in Camp Oasis with a $5,000 grant! From Left to right: Bill Meury, Allergan Foundation board member and Executive VP, Chief Commercial Officer; Jonathon Kellerman, Allergan Foundation board member and Executive VP, Global Chief Compliance Officer; Denise Desmond, Crohn’s & Colitis Foundation Orange County Chapter, Executive Director, Gwyn Grenrock, Executive Director of The Allergan Foundation; and Alex Kelly, Allergan Foundation President and Executive VP, Chief Communications Officer.
Landmark Study to Compare the Effectiveness of Biologic or Small Molecule Therapies in Inflammatory Bowel Diseases (IBD) Receives FundingMay 17, 2018
Crohn’s disease (CD) and ulcerative colitis (UC), collectively referred to as inflammatory bowel diseases (IBD), which may affect as many as 3 million Americans, cost over $6 billion annually, and cause substantial patient morbidity, missed work and school, and diminished quality of life. Currently, anti-TNF therapy is considered first line treatment for moderate-to-severe IBD. However, up to 80 percent of patients do not respond or, ultimately, lose response to anti-TNF. New treatments provide additional options from which to choose, however, there are no head-to-head studies that compare these new treatments.
Clinical trial recruitment is the biggest barrier to the development and approval of new treatments. In order to understand patient perceptions and improve recruitment, the Crohn’s & Colitis Foundation conducted in-person focus groups over a four-month period in 2016, the results of which are published in the paper "Crohn’s disease and ulcerative colitis patient perspectives on clinical trials and participation."
Leading Patient & Professional Organizations Announce Funding to Improve Communications & Address Shared Decision-making in Inflammatory Bowel DiseasesApril 17, 2018
The Crohn’s & Colitis Foundation (Foundation) and the American Gastroenterological Association (AGA), in collaboration with Pfizer, Inc., have announced the results of a request for proposal (RFP) to address interventions that aim to improve shared decision-making and promote effective health communication between patients with inflammatory bowel disease (IBD) and their clinicians.
The Crohn's & Colitis Foundation Selects Diversigen, Inc. as a Preferred Provider for Metagenomics and Microbiome Analysis ServicesApril 11, 2018
Diversigen Inc. is pleased to announce that the company has been selected by the Crohn’s & Colitis Foundation as a preferred provider for metagenomics and microbiome analysis services and to serve as a central lab for the generation of high quality microbiome data to be incorporated into the IBD Plexus® platform.
exploring the relationship between accutane and ulcerative colitis